Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity

Alemtuzumab is a monoclonal antibody that causes rapid depletion of CD52-expressing immune cells. It has proven to be highly efficacious in active relapsing–remitting multiple sclerosis; however, the high risk of secondary autoimmune disorders has greatly complicated its use. Thus, deeper insight in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruck, Tobias, Barman, Sumanta, Schulte-Mecklenbeck, Andreas, Pfeuffer, Steffen, Steffen, Falk, Nelke, Christopher, Schroeter, Christina B., Willison, Alice, Heming, Michael, Müntefering, Thomas, Melzer, Nico, Krämer, Julia, Lindner, Maren, Riepenhausen, Marianne, Gross, Catharina C., Klotz, Luisa, Bittner, Stefan, Muraro, Paolo A., Schneider-Hohendorf, Tilman, Schwab, Nicholas, Meyer zu Hörste, Gerd, Goebels, Norbert, Meuth, Sven G., Wiendl, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166548/
https://www.ncbi.nlm.nih.gov/pubmed/35661859
http://dx.doi.org/10.1093/brain/awac064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166548/
https://www.ncbi.nlm.nih.gov/pubmed/35661859
http://dx.doi.org/10.1093/brain/awac064

Ejemplares similares